Brain Imaging Changes Associated With Risk Factors for Cardiovascular and Cerebrovascular Disease in Asymptomatic Patients

Joseph I. Friedman, MD,* Cheuk Y. Tang, PhD,* Hans J. de Haas, BSc, BA, Lisa Changchien, MD,* Georg Goliasch, MD, PhD, Puneet Dabas, MD, Victoria Wang, BS, Zahi A. Fayad, PhD, Valentin Fuster, MD, Jagat Narula, MD

CME Objective for This Article: At the end of this activity the reader should be able to: 1) review brain structural and functional imaging changes in persons harboring risk factors for cardiovascular and cerebrovascular disease, but with no clinical manifestations of either cardiovascular or cerebrovascular disease; 2) understand that cognitive impairment is an important clinical manifestation of these vascular risk factor-related structural and functional brain imaging changes in these asymptomatic persons; and 3) review the evidence demonstrating that effective management of these modifiable vascular risk factors reduces the severity of associated brain imaging abnormalities and related cognitive impairments; suggesting that adequate treatment of vascular risk factors may have beneficial effects on brain function.

CME Editor Disclosure: JACC: Cardiovascular Imaging CME Editor Ragavendra R. Baliga, MD, has reported that he has no relationships to disclose.

Author Disclosures: Dr. Narula has received research grants from GE Healthcare and Philips Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz).

CME Term of Approval
Issue Date: October 2014
Expiration Date: September 30, 2015

From the *Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York; yDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York; zClinical Neuroscience Center, Pilgrim Psychiatric Center, West Brentwood, New York; kDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York; wZena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York; {Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; and the #Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York. Dr. Narula has received research grants from GE Healthcare and Philips Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received March 3, 2014; revised manuscript received June 9, 2014, accepted June 10, 2014.
Brain Imaging Changes Associated With Risk Factors for Cardiovascular and Cerebrovascular Disease in Asymptomatic Patients

ABSTRACT

Reviews of imaging studies assessing the brain effects of vascular risk factors typically include a substantial number of studies with subjects with a history of symptomatic cardiovascular or cerebrovascular disease and/or events, limiting our ability to disentangle the primary brain effects of vascular risk factors from those of resulting brain and cardiac damage. The objective of this study was to perform a systematic review of brain changes from imaging studies in patients with vascular risk factors but without clinically manifest cardiovascular or cerebrovascular disease or events. The 77 studies included in this review demonstrate that in persons without symptomatic cardiovascular, cerebrovascular, or peripheral vascular disease, the vascular risk factors of hypertension, diabetes mellitus, obesity, hyperlipidemia, and smoking are all independently associated with brain imaging changes before the clinical manifestation of cardiovascular or cerebrovascular disease. We conclude that the identification of brain changes associated with vascular risk factors, before the manifestation of clinically significant cerebrovascular damage, presents a window of opportunity wherein adequate treatment of these modifiable vascular risk factors may prevent the development of irreversible deleterious brain changes and potentially alter patients’ clinical course. (J Am Coll Cardiol Img 2014;7:1039–53) © 2014 by the American College of Cardiology Foundation.

METHODS

This systematic review was conducted following the guidelines of the PRISMA statement (10).

STUDY SELECTION. Studies included in this review report the results of brain imaging investigations of persons with any of the following risk factors for cardiovascular or cerebrovascular disease: hypertension (HTN), diabetes mellitus (DM), increased adiposity, hyperlipidemia, smoking, and metabolic syndrome (MetS). Included studies assessed the association between these VRFs and findings with all brain structural and functional imaging modalities available. This review is limited to English-language publications from 1980 to August 31, 2013. Published studies were excluded if: 1) subjects were younger
than 18 years of age; 2) subjects carried a diagnosis of dementia (i.e., Alzheimer’s disease, VaD) or other primary neurological condition associated with brain dysfunction; 3) subjects had a diagnosis of a psychiatric disorder except depression; 4) subjects had a history of cerebrovascular accident, transient ischemic attack, symptomatic infarcts on magnetic resonance imaging (MRI), or the methodology made no mention of the exclusion of such subjects; 5) ≈5% of the study cohort had a diagnosis of coronary artery disease, myocardial infarction, congestive heart failure, and peripheral vascular disease and if a <5% prevalence rate was present in the sample, no subanalyses were carried out excluding subjects with those diagnoses or no statistical adjustment was performed to control for the effects of these diagnoses; and 6) no statistical correction for the effects of age, sex, and the effects of other VRFs not the primary focus of investigation.

SEARCH STRATEGY. Studies were identified by searching the following electronic databases: MEDLINE, CINAHL, and Cochrane Database of Systematic Review using the following search terms: “vascular risk factor,” “hypertension,” “diabetes,” “obesity,” “hyperlipidemia,” “smoking,” “metabolic syndrome,” “brain,” “imaging,” “magnetic resonance imaging (MRI),” “fMRI,” “DTI,” “PET,” and “computed tomography (CT).” References of review papers were searched to identify studies that might have been overlooked in the initial search. Six of the authors (J.F., C.T., G.G., H.D., L.C., and P.D.) reviewed abstracts of all citations from the search and the full papers for inclusion. The final decision to include studies was on the basis of the inclusion and exclusion criteria and a review of the full text papers by the primary author (J.I.F.).

DATA EXTRACTION. We developed a data extraction sheet and had 6 review authors (J.F., C.T., G.G., H.D., L.C., and P.D.) extract the following data from included studies with the primary author (J.I.F.), checking the extracted data for its integrity and accuracy: 1) number of study subjects in each group; 2) demographic characteristics of subjects (i.e., age, sex, ethnicity); 3) VRF being assessed; 4) presence of symptomatic cardiovascular, cerebrovascular, or peripheral vascular disease; 5) whether prevalence of vascular disease ≥5%, was a subanalysis performed excluding those subjects with disease or were statistical analyses performed to control for the effects of vascular disease; 6) the presence of other VRFs and, if present, was a subanalysis performed excluding those subjects with multiple risk factors or were statistical analyses performed to control for the effects of the other VRFs; 8) onset (i.e., mid-life, late life) and length of exposure to risk factor; 9) treatment of VRFs, analyses of effects of treatment; 9) imaging modality; 10) all structural and functional imaging outcomes; and 11) correlations between imaging variables and neuropsychological test performance.

RESULTS

To better understand the data presented in this review, a summary of neuroimaging acronyms referenced herein is provided in Table 1. A total of 77 published studies of the effects of HTN, DM, increased adiposity, hyperlipidemia, smoking, and MetS on brain structural and functional imaging findings are included in this review. A concise summary of the more salient findings of the effects of these VRFs and their treatment on brain structure and function is presented in Table 2.

I. HYPERTENSION. A total of 22 published brain imaging studies of HTN effects are included in this review (Online Table 1).

Structural brain changes. Global changes. Whole-brain volume reduction has been associated with a diagnosis of HTN (11). Other global changes associated with HTN include brain cerebrospinal fluid space enlargement (12,13).

Gray matter changes. HTN has been associated with brain gray matter (GM) volume reductions in cross-sectional studies, with a heterogeneous pattern of these volume reductions between studies (12-14). It is possible that the confounding effects of aging may partially contribute to the discrepancies in location of HTN-related GM reductions between studies. In support of this supposition is the finding of Strassburger et al. (13), who, when considering the interaction of aging and a diagnosis of HTN, extended their findings from the thalamus to include atrophy of the frontal cortices of the brain. However, when a more continuous variable such as blood pressure (BP) was used, a more complex U-shaped association of brain cortical atrophy with concurrent diastolic blood pressure (DBP) emerges (15). DBP outside an ideal range of 65 to 74 mm Hg has been associated with brain cortical atrophy, including both elevated (>85 mm Hg) and reduced (<65 mm Hg) DBP (15).

Longitudinal relationships between BP and brain GM volume have been more inconsistent. These inconsistencies include some reports of HTN-associated brain GM volume loss over time (16), whereas some
<table>
<thead>
<tr>
<th>Imaging Acronym</th>
<th>Acronym Expansion</th>
<th>Imaging Modality</th>
<th>Explanation of Imaging Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>Axial diffusivity</td>
<td>MRI (DTI)</td>
<td>The measure of restriction along the axis of the axons (perpendicular to the direction of radial diffusivity). AD is a more specific index of axonal degeneration.</td>
</tr>
<tr>
<td>BOLD</td>
<td>Blood oxygen level dependent</td>
<td>MRI</td>
<td>The principal mechanism of signal contrast in fMRI produced by a combination of brain neuronal oxygen consumption (oxygenation state of hemoglobin is measured) and blood flow. The BOLD signal is associated with brain neuronal activation, more activation — increased BOLD.</td>
</tr>
<tr>
<td>Cho</td>
<td>Choline</td>
<td>MRS</td>
<td>A metabolite quantified in the brain by MRS. Cho is a marker of cellular membrane turnover reflecting cellular proliferation. Increased Cho can be seen in malignancy, infarction, and inflammation.</td>
</tr>
<tr>
<td>Cr</td>
<td>Creatine</td>
<td>MRS</td>
<td>A metabolite quantified in the brain by MRS. Cr is considered a marker of intracellular metabolism. It is considered a stable brain metabolite.</td>
</tr>
<tr>
<td>DA D₂ receptor</td>
<td>Dopamine D₂ receptor subtype occupancy</td>
<td>PET (¹⁵C)raclopride PET</td>
<td>[¹⁵C]Raclopride ligand PET scanning is used to determine changes in brain DA D₂ receptor binding potential, which indexes changes in DA release in the brain.</td>
</tr>
<tr>
<td>DMN</td>
<td>Default mode network</td>
<td>MRI (fMRI)</td>
<td>A brain functional network, the activity of which is measured during resting state fMRI. This network of brain regions is normally engaged when patients are left to think to themselves undisturbed; composed of medial temporal lobe, prefrontal cortex, posterior cingulate, and parietal cortex.</td>
</tr>
<tr>
<td>DTI</td>
<td>Diffusion tensor imaging</td>
<td>MRI</td>
<td>DTI produces MRI indexes of white matter integrity and axonal bundle formation and geometries.</td>
</tr>
<tr>
<td>FA</td>
<td>Fractional anisotropy</td>
<td>MRI (DTI)</td>
<td>An index of myelination or white matter integrity and/or organization. FA is expressed as a number on a scale between 0 and 1, without any unit of measure. The greater the FA, the greater the integrity/organization of the white matter tract.</td>
</tr>
<tr>
<td>FC</td>
<td>Functional connectivity</td>
<td>MRI or PET</td>
<td>Time synchronous activation between multiple distant brain regions.</td>
</tr>
<tr>
<td>FDG-PET</td>
<td>Fluorodeoxyglucose positron emission tomography</td>
<td>PET</td>
<td>Scanning technique measuring glucose metabolism in the brain using a radiolabeled glucose analogue.</td>
</tr>
<tr>
<td>fMRI</td>
<td>Functional magnetic resonance imaging</td>
<td>MRI</td>
<td>Stimulus-driven brain activation measured from the changes in oxygenation states of hemoglobin.</td>
</tr>
<tr>
<td>GM volume</td>
<td>Gray matter volume</td>
<td>MRI</td>
<td>The volume of the brain GM can be expressed as a global or region-specific measure. GM in the brain contains the cell bodies, dendrites, and axon terminals of neurons.</td>
</tr>
<tr>
<td>MAO-A</td>
<td>Monoamine oxidase A</td>
<td>PET (¹¹C)clorgyline PET</td>
<td>MAO-A metabolizes serotonin, norepinephrine, and dopamine. PET using [¹¹C]clorgyline measures brain MAO-A.</td>
</tr>
<tr>
<td>MAO-B</td>
<td>Monoamine oxidase B</td>
<td>PET (deuterium substituted [¹¹C]-deprenyl PET)</td>
<td>MAO-B primarily metabolizes dopamine. PET using deuterium substituted [¹¹C]-deprenyl measures brain MAO-B.</td>
</tr>
<tr>
<td>MD</td>
<td>Mean diffusivity</td>
<td>MRI (DTI)</td>
<td>Also referred to as the apparent diffusion coefficient (ADC). It is a measure of diffusion (Brownian motion) of water molecules in tissue measured in mm²/s. MD is affected by restricted spaces, barriers such as cell membranes, tubules, and macromolecules. ADC maps of the brain can be generated, and good diffusion is bright on these maps.</td>
</tr>
<tr>
<td>MRS</td>
<td>Magnetic resonance spectroscopy</td>
<td>MRS</td>
<td>An imaging technique based on MRI that allows one to visualize certain metabolite concentrations in brain tissue; either single-voxel spectra or metabolite images can be produced (MRS imaging). The major peaks of the ¹H-MRS spectrum (each peak represent a metabolite) reported in this review include N-acetylaspartate (NAA), creatine (Cr), and choline (Cho) containing phospholipids.</td>
</tr>
<tr>
<td>NAA</td>
<td>N-Acetylaspartate</td>
<td>MRS</td>
<td>A metabolite quantified in the brain by MRS. NAA is considered a metabolic marker reflecting the functional status of neurons and axons in the brain, with a decrease indicating neuronal or axonal loss or dysfunction.</td>
</tr>
<tr>
<td>NAA/Cr, NAA/Cho</td>
<td>N-Acetylaspartate ratios with Cr/Cho</td>
<td>MRS</td>
<td>The concentration of Cr is relatively constant and is considered a stable brain metabolite; therefore, it is used as an internal reference for calculating metabolite ratios such as NAA. Cho is also used as an internal reference for calculating NAA ratios.</td>
</tr>
</tbody>
</table>

Continued on the next page
report no volume loss (17,18). In addition, some studies report higher DBP associated with greater brain GM volume loss over time (15), whereas others report higher SBP associated with greater volume loss (19).

When considering the effects of pharmacological treatment of HTN on brain GM volumetric changes, 2 outcomes emerge: 1) pharmacological treatment of HTN fails to prevent increased brain GM loss over time (14,16,19); and 2) pharmacological treatment of HTN results in either a reduction or acceleration of brain GM volume loss over time, the direction dependent on the timing of treatment initiation and the magnitude of BP reduction. For example, investigators have shown that higher DBP in midlife predicts more brain GM volume loss late in life when antihypertensive medication is not used, whereas this relationship is lost when antihypertensive medication is used (15). However, when antihypertensive use is initiated late in life instead of midlife, it is associated with more pronounced brain GM loss, particularly when there is a steeper decrease in DBP (15).

White matter changes. Cross-sectional investigations have shown a diagnosis of HTN to be associated with loss of prefrontal brain white matter (WM) volume (14) and a variable pattern of MRI-identified WM hyperintensity (WMH) increases with respect to overall burden and location in the brain (11,13,14,19). WMHs are localized pathological changes in the white matter of the brain due to chronic hypoperfusion by arteriolosclerotic changes to the brain microvasculature, and thus WMHs can be considered an MRI index of brain microvascular disease. Indeed, the relationship between HTN and the MRI index of brain microvascular pathology assumes a J-shaped function when nocturnal BP changes are considered, wherein hypertensive patients with extreme nocturnal BP dips (>20% decrease from awake systolic blood pressure [SBP]) and those with no significant nocturnal dips (<10% decrease from awake SBP) show an increased MRI index of brain microvascular

<table>
<thead>
<tr>
<th>Imaging Acronym</th>
<th>Acronym Expansion</th>
<th>Imaging Modality</th>
<th>Explanation of Imaging Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>rCBF</td>
<td>Regional cerebral blood flow</td>
<td>$^{99}$Tc-HMPAO SPECT</td>
<td>The volume of blood traversing a brain region per unit of time (ml/100 g/min). rCBF is measured using SPECT (single-photon emission tomography) with $^{99}$Tc-HMPAO, $^{133}$Xe SPECT, $[^{15}]$H$_2$O PET, or dynamic susceptibility contrast MRI.</td>
</tr>
<tr>
<td>rCBV</td>
<td>Regional cerebral blood volume</td>
<td>MRI</td>
<td>Total volume of blood traversing a brain region measured in ml/100 g of brain tissue, commonly obtained using contrast-enhanced MRI.</td>
</tr>
<tr>
<td>rCMRglu</td>
<td>Regional cerebral glucose metabolic rate</td>
<td>PET (fluorodeoxyglucose-PET)</td>
<td>Metabolic rate of glucose in the brain.</td>
</tr>
<tr>
<td>RD</td>
<td>Radial diffusivity</td>
<td>MRI (DTI)</td>
<td>Measures the degree of restriction due to the presence of the myelin sheath (i.e., perpendicular to the axonal fibers). Radial diffusivity is modulated by myelin in white matter and therefore is a more specific index of myelin pathology.</td>
</tr>
<tr>
<td>rsFDG-PET</td>
<td>Resting state fluorodeoxyglucose positron emission tomography</td>
<td>PET</td>
<td>Glucose metabolic activity measured during resting state.</td>
</tr>
<tr>
<td>rsfMRI</td>
<td>Resting state functional MRI</td>
<td>MRI</td>
<td>Functional connectivity measured using MRI with a subject at wakeful rest and not performing any goal-oriented task.</td>
</tr>
<tr>
<td>V$f$</td>
<td>Total volume of the radioligand 2FA corrected for fraction in free plasma</td>
<td>PET (2FA-PET)</td>
<td>The 2FA radioligand PET imaging procedure is used to quantify the $\alpha$-4$/\beta$-2 nicotinic acetylcholine receptor in the brain.</td>
</tr>
<tr>
<td>WMH volume</td>
<td>White matter volume</td>
<td>MRI</td>
<td>Volume of the brain white matter can be expressed as a global or region-specific measure. White matter is composed of axons connecting different regions of gray matter in the brain to each other.</td>
</tr>
</tbody>
</table>

Note: The commonly accepted categorization of WMH is as follows: 1. PVWMH 2. DWMH

1. WMH lining the lateral ventricles.
2. WMH located in the remaining WM, not adjacent to the lateral ventricles.

$^{99}$Tc-HMPAO = technetium 99 hexamethyl-propyl creatinine oxime.
pathology, whereas those with less extreme nocturnal BP dips (10% to 20% decrease from awake SBP) show no increases in the MRI index of brain microvascular pathology (20). Over time, the burden of the MRI index of brain microvascular pathology increases in hypertensive patients (19), with some reports showing SBP increases to be more important in this process (17,21), and others DBP increases (22,23). Finally, the impaired cognitive function of hypertensive patients has been attributed to this increased MRI index of brain microvascular pathology (22). The pharmacological treatment of HTN has been reported to increase the MRI index of brain microvascular pathology compared with untreated hypertensive patients (24). The same study also reported greater disorganization of the brain white matter fiber tracts that connect brain regions (indexed on MRI as lower fractional anisotropy values) in treated compared with untreated hypertensive patients (24). However, these results are confounded by the

---

### TABLE 2 Summary of the Effects of VRFs and Their Treatment on Structural and Functional Brain Imaging

<table>
<thead>
<tr>
<th>VRF</th>
<th>Structural Imaging Findings</th>
<th>Treatment Effects on VRF-Related Structural Imaging Findings</th>
<th>Functional Imaging Findings</th>
<th>Treatment Effects on VRF-Related Functional Imaging Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN</td>
<td>1. HTN is associated with whole-brain volumetric reductions.</td>
<td>1. Higher DBP is associated with more cortical atrophy over 20 years in untreated hypertensive patients, but not in treated hypertensive patients.</td>
<td>1. HTN is associated with reduced resting state gCBF and rCBF.</td>
<td>1. Antihypertensive treatment reverses/mutes HTN-related decreases in resting state and cognitive task activated gCBF and rCBF.</td>
</tr>
<tr>
<td></td>
<td>2. HTN is associated with a variable pattern of gray matter volumetric reductions across studies.</td>
<td>2. Reduction in BP to normotensive levels in hypertensive patients with treatment fails to prevent gray matter loss over 1 year.</td>
<td>2. The quality of BP control in hypertensive patients is positively correlated with resting state gCBF and rCBF.</td>
<td>2. The quality of BP control in hypertensive patients is positively correlated with resting state gCBF and rCBF.</td>
</tr>
<tr>
<td></td>
<td>3. HTN is associated with a variable pattern of increased WMH burden across studies.</td>
<td>3. Antihypertensive use in hypertensive patients in late life, but not midlife is associated with more cortical atrophy.</td>
<td>3. Antihypertensive treatment increases correlations in cognitive task-related rCBF between regions associated with task performance (limited evidence).</td>
<td>3. Antihypertensive treatment increases correlations in cognitive task-related rCBF between regions associated with task performance (limited evidence).</td>
</tr>
<tr>
<td></td>
<td>4. Hypertensive patients with extreme or no nocturnal dips in SBP have greater WMH burden compared with hypertensive patients with moderate nocturnal dips in BP.</td>
<td>4. After 36 months of antihypertensive treatment, there is a return to pre-treatment reduced levels of CBF in hypertensive patients (limited evidence).</td>
<td>4. After 36 months of antihypertensive treatment, there is a return to pre-treatment reduced levels of CBF in hypertensive patients (limited evidence).</td>
<td>4. After 36 months of antihypertensive treatment, there is a return to pre-treatment reduced levels of CBF in hypertensive patients (limited evidence).</td>
</tr>
<tr>
<td>DM</td>
<td>1. No consensus on the association of DM with global GM volumetric reductions.</td>
<td>1. The quality of glycemic control (HbA1c) is associated with the magnitude of WMH burden (limited evidence).</td>
<td>1. DM is associated with lower resting state rCBF (limited evidence).</td>
<td>No treatment data available.</td>
</tr>
<tr>
<td></td>
<td>2. No consensus on the association of DM with WMH burden.</td>
<td>2. The quality of glycemic control (HbA1c) is associated with FA in the corona radiata and optic radiations (limited evidence).</td>
<td>2. DM is associated with a redistributed pattern of cognitive task-related rCMRglu (limited evidence).</td>
<td>No treatment data available.</td>
</tr>
<tr>
<td></td>
<td>3. Type 1 DM is associated with a variable pattern of WM FA reductions across studies.</td>
<td>3. Types 1 and 2 DM are associated with reduced functional connectivity in default mode network and other various cognitive networks on fMRl.</td>
<td>3. Types 1 and 2 DM are associated with reduced functional connectivity in default mode network and other various cognitive networks on fMRl.</td>
<td>No treatment data available.</td>
</tr>
<tr>
<td>Adiposity</td>
<td>1. Increased adiposity is associated with decreased total cerebral volume.</td>
<td>1. Greater aerobic fitness is associated with greater FA in the cingulum (limited data).</td>
<td>1. Increased BMI is associated with decreased resting state rCBF (limited data).</td>
<td>No treatment data available.</td>
</tr>
<tr>
<td></td>
<td>2. Increased BMI is associated with a variable pattern of GM volumetric reductions across studies.</td>
<td></td>
<td>2. Increased BMI is associated with reduced rCMRglu in bilateral prefrontal and anterior cingulate regions (limited data).</td>
<td>No treatment data available.</td>
</tr>
<tr>
<td></td>
<td>3. No consensus on the association of BMI with WM volumetric changes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. No association between indexes of adiposity and burden of WMMs (limited data).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1. Higher total cholesterol and LDL are associated with lower GM volume (limited evidence).</td>
<td>1. No effects of lipid-lowering medications on the LDL- or cholesterol-related FA decreases observed in the right hemisphere (limited evidence).</td>
<td>1. Hypertriglyceridemia is associated with temporal lobe hypoperfusion.</td>
<td>The association between higher total cholesterol with lower rCMRglu in the precuneus, prefrontal, parietotemporal, and frontal regions remain significant after controlling for statin use (limited data).</td>
</tr>
<tr>
<td></td>
<td>2. Higher total cholesterol and LDL are associated with lower FA in WM of the right hemisphere (limited evidence).</td>
<td></td>
<td>2. Higher serum total cholesterol is associated with lower rCMRglu in the precuneus, prefrontal, parietotemporal, and frontal regions (limited evidence).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. No association between familial hypercholesterolemia and burden of WMHs.</td>
<td></td>
<td>3. Higher cholesterol-related genetic scores (CREGG) are associated with lower rCMRglu in the posterior cingulate, precuneus, parietotemporal, and frontal regions (limited evidence).</td>
<td></td>
</tr>
</tbody>
</table>

Continued on the next page
significantly younger mean age of the untreated hypertensive patient subgroup compared with the treated group (57.6 vs. 68.2).

**Functional brain changes. Cerebral blood flow changes.** There is consensus among reports that a diagnosis of HTN is associated with abnormally reduced blood flow during rest throughout the whole brain (global cerebral blood flow) and in discrete brain areas (regional cerebral blood flow), and is associated with bidirectional alterations in cognitive test performance-related activation of regional brain blood flow, with some brain regions showing abnormally reduced blood flow and some abnormally increased blood flow (25–30). The quality of BP control in hypertensive patients has been positively correlated with brain blood flow in specific regions observed during rest in both cross-sectional (29,30) and longitudinal (25) studies. These data would suggest a potential for antihypertensive treatment to reverse the HTN-associated abnormally decreased brain regional blood flow observed during rest. Indeed, both global and regional brain blood flow observed during rest is lower in persons with untreated HTN compared with normotensive persons, whereas treatment with antihypertensive medication nearly normalizes regional brain blood flow at rest in hypertensive persons (26,29,30), with a treatment period as short as 6 months to produce these effects (26,31). However, there is evidence, although limited, that these antihypertensive treatment-related improvements in brain blood flow observed at rest in hypertensive patients may be transient, wherein such improvements have been observed at 6, 12, and 24 months after initiation of antihypertensive treatment, but returned to pretreatment abnormally low levels after 36 months of treatment (31).

The bidirectional nature of regional brain blood flow changes observed during cognitive test performance in persons with HTN may reflect compensatory mechanisms. For example, hypertensive patients show greater left brain hemispheric blood flow increases while performing tests of attention and memory, whereas normotensive patients show greater right hemispheric brain blood flow increases while performing the same tests (27). These data suggest that regional blood flow changes in the brains of hypertensive patients performing cognitive tests redistribute to alternate brain regions to maintain successful performance of these cognitive tests. This
assertion is supported by observations that hypertensive patients with better memory performance show less HTN-related abnormal increases in blood flow in the prefrontal region and less HTN-related abnormal muting of blood flow increases in right hippocampal region (28), 2 important brain blood flow changes necessary for normal memory performance. Also, there appears to be a secondary brain blood flow compensatory mechanism manifested as an increase in the correlation of blood flow rates between brain regions in hypertensive persons performing cognitive tests. Specifically, hypertensive patients have shown increased linkage of brain blood flow increases in the hippocampal and prefrontal regions compared with normotensive persons while performing memory tests (28). Antihypertensive treatment appears to facilitate this secondary brain blood flow compensatory mechanism observed in hypertensive patients. For example, 1 year of treatment with either lisinopril or atenolol results in greater linkage of blood flow increases between prefrontal, parietal, prefrontal, and hippocampal brain regions, regions involved in specific memory processes (32). Additionally, diuretic treatment over a period of 6 months has been shown to improve performance on tests of several different cognitive abilities; these improvements correlate with the magnitude of blood flow increases in several brain regions (26) (Online Table 1).

Cerebral glucose metabolic changes. Using positron emission tomography, patients with HTN at rest have been shown to have reduced rates of brain glucose metabolism in regions supplied by the perforator arteries of the circle of Willis (33) and reduced correlations between brain glucose metabolic rates in these regions (33), suggestive of a reduction in connectivity between brain regions in hypertensive persons performing cognitive tests. Specifically, hypertensive patients have shown increased linkage of brain blood flow increases in the hippocampal and prefrontal regions compared with normotensive persons while performing memory tests (28). Antihypertensive treatment appears to facilitate this secondary brain blood flow compensatory mechanism observed in hypertensive patients. For example, 1 year of treatment with either lisinopril or atenolol results in greater linkage of blood flow increases between prefrontal, parietal, prefrontal, and hippocampal brain regions, regions involved in specific memory processes (32). Additionally, diuretic treatment over a period of 6 months has been shown to improve performance on tests of several different cognitive abilities; these improvements correlate with the magnitude of blood flow increases in several brain regions (26) (Online Table 1).

Cerebral glucose metabolic changes. Using positron emission tomography, patients with HTN at rest have been shown to have reduced rates of brain glucose metabolism in regions supplied by the perforator arteries of the circle of Willis (33) and reduced correlations between brain glucose metabolic rates in these regions (33), suggestive of a reduction in connectivity between brain regions in hypertensive persons performing cognitive tests. Specifically, hypertensive patients have shown increased linkage of brain blood flow increases in the hippocampal and prefrontal regions compared with normotensive persons while performing memory tests (28). Antihypertensive treatment appears to facilitate this secondary brain blood flow compensatory mechanism observed in hypertensive patients. For example, 1 year of treatment with either lisinopril or atenolol results in greater linkage of blood flow increases between prefrontal, parietal, prefrontal, and hippocampal brain regions, regions involved in specific memory processes (32). Additionally, diuretic treatment over a period of 6 months has been shown to improve performance on tests of several different cognitive abilities; these improvements correlate with the magnitude of blood flow increases in several brain regions (26) (Online Table 1).

Cerebral glucose metabolic changes. Using positron emission tomography, patients with HTN at rest have been shown to have reduced rates of brain glucose metabolism in regions supplied by the perforator arteries of the circle of Willis (33) and reduced correlations between brain glucose metabolic rates in these regions (33), suggestive of a reduction in connectivity between brain regions in hypertensive persons performing cognitive tests. Specifically, hypertensive patients have shown increased linkage of brain blood flow increases in the hippocampal and prefrontal regions compared with normotensive persons while performing memory tests (28). Antihypertensive treatment appears to facilitate this secondary brain blood flow compensatory mechanism observed in hypertensive patients. For example, 1 year of treatment with either lisinopril or atenolol results in greater linkage of blood flow increases between prefrontal, parietal, prefrontal, and hippocampal brain regions, regions involved in specific memory processes (32). Additionally, diuretic treatment over a period of 6 months has been shown to improve performance on tests of several different cognitive abilities; these improvements correlate with the magnitude of blood flow increases in several brain regions (26) (Online Table 1).

Cerebral glucose metabolic changes. Using positron emission tomography, patients with HTN at rest have been shown to have reduced rates of brain glucose metabolism in regions supplied by the perforator arteries of the circle of Willis (33) and reduced correlations between brain glucose metabolic rates in these regions (33), suggestive of a reduction in connectivity between brain regions in hypertensive persons performing cognitive tests. Specifically, hypertensive patients have shown increased linkage of brain blood flow increases in the hippocampal and prefrontal regions compared with normotensive persons while performing memory tests (28). Antihypertensive treatment appears to facilitate this secondary brain blood flow compensatory mechanism observed in hypertensive patients. For example, 1 year of treatment with either lisinopril or atenolol results in greater linkage of blood flow increases between prefrontal, parietal, prefrontal, and hippocampal brain regions, regions involved in specific memory processes (32). Additionally, diuretic treatment over a period of 6 months has been shown to improve performance on tests of several different cognitive abilities; these improvements correlate with the magnitude of blood flow increases in several brain regions (26) (Online Table 1).

Cerebral glucose metabolic changes. Using positron emission tomography, patients with HTN at rest have been shown to have reduced rates of brain glucose metabolism in regions supplied by the perforator arteries of the circle of Willis (33) and reduced correlations between brain glucose metabolic rates in these regions (33), suggestive of a reduction in connectivity between brain regions in hypertensive persons performing cognitive tests. Specifically, hypertensive patients have shown increased linkage of brain blood flow increases in the hippocampal and prefrontal regions compared with normotensive persons while performing memory tests (28). Antihypertensive treatment appears to facilitate this secondary brain blood flow compensatory mechanism observed in hypertensive patients. For example, 1 year of treatment with either lisinopril or atenolol results in greater linkage of blood flow increases between prefrontal, parietal, prefrontal, and hippocampal brain regions, regions involved in specific memory processes (32). Additionally, diuretic treatment over a period of 6 months has been shown to improve performance on tests of several different cognitive abilities; these improvements correlate with the magnitude of blood flow increases in several brain regions (26) (Online Table 1).

FIGURE 1 How Can Brain Circuit Connectivity Inform Us About Cardiovascular Health?

A 3-dimensional visualization of normal brain white matter tracts generated by tractography analysis of data collected by diffusion tensor imaging (DTI). This analysis uses special techniques of magnetic resonance imaging and computer-based image analysis to provide insight into the complex white matter connections between neural networks formed by short connections among different cortical and subcortical brain regions. DTI can be used to evaluate the integrity of these white matter connections. Data from this review demonstrate that the same risk factors for cardiovascular disease also compromise the integrity of these white matter connections and thus the normal physiological pattern of synchronized activation/deactivation of these interconnected brain regions (also presented in this review). These disruptions result in subtle cognitive impairments. Although not easily recognizable, we hypothesize that they are sufficient to adversely affect the adoption of primary prevention measures for cardiovascular events. The use of sophisticated neuroimaging techniques such as DTI to assess changes in structure of brain connectivity and related neuroimaging techniques to assess functional changes in brain connectivity in persons at risk of cardiovascular disease and events will enhance our understanding of the role of the brain in the progression from cardiovascular risk factor to symptomatic disease.
type 2 DM and MRI indexes of brain microvascular disease have been more inconsistent. Some studies show significant associations between a diagnosis of type 2 DM and an increased presence of MRI indexes of brain microvascular disease (34–36,39), whereas others show no such association with type 2 DM (37,38,41). However, even in the studies that report significant associations between type 2 DM and brain microvascular disease, the type and location of the MRI indexes of brain microvascular disease differ between studies (34–36,39) (Online Table 2). Moreover, limited data suggest the quality of glycemic control affects the amount of observed MRI indexes of brain microvascular disease (35).

MRI indexes of the structure (i.e., diffusivity) and organization (i.e., fractional anisotropy) of brain WM connecting tracts have also been reported to be affected by a diagnosis of DM. For example, type 1 DM has been associated with more disorganized WM tracts in several brain regions (42,43), with better long-term glycemic control associated with a greater degree of preservation of the organization of the brain WM tracts in some of these regions (42). In addition, a diagnosis of DM has also been associated with increased myelin degeneration in a number of the same brain regions in which increased WM tract disorganization has been observed (43). Finally, increased brain WM tract disorganization in several regions affected by DM has been associated with poorer cognitive performance (42).

**Functional brain changes. Cerebral blood flow changes.**

Over all brain regions investigated, regional blood flow observed at rest is lower in patients with type 2 DM (34), and the normal increase in blood flow associated with hypercapnea is also lower in patients with type 2 DM (34).

**Cerebral glucose metabolic changes.** Similar to the brain blood flow changes observed in patients with HTN, both type 2 DM and pre-diabetes are associated with a bidirectional alteration and a redistributed pattern of brain glucose metabolism in patients performing tests of memory function (2 proposed compensatory mechanisms for the brain metabolism dysfunction that accompanies DM). Specifically, patients with type 2 DM and pre-diabetes show a more widespread pattern of brain glucose metabolism, extending to brain regions adjacent to those activated in non-diabetic patients while performing tests of memory function (44) (Online Table 2). Moreover, better performance of pre-diabetic and diabetic patients on memory tests has been associated with a greater ability to increase brain glucose metabolism during performance of these memory tests in regions normally activated (44). Furthermore, a greater decrease in the ability of body’s cells to respond to the actions of the insulin has been associated with reduced brain glucose metabolism during rest in a number of brain regions (44) (Online Table 2).

**Brain regional activation (fMRI) changes.** Patients with type 2 DM have demonstrated reduced synchronized activity between several specific brain regions, observed by functional magnetic resonance imaging (fMRI) (reduced functional connectivity), regions normally engaged when patients are left to think to themselves undisturbed (referred to as the default mode network) (40,45) (Online Table 2). Moreover, the reduction in functional connectivity of this free-thinking brain network is accompanied by impaired cognitive performance (45). When parsing patients with type 1 DM on the basis of the presence or absence of microangiopathy (a group of microvascular abnormalities including vessel wall remodeling, media hypertrophy, and increased vascular wall stiffness), a mixed pattern of functional connectivity changes compared with nondiabetic patients emerges. Patients with type 1 DM and microangiopathy have demonstrated decreased functional connectivity compared with nondiabetic patients in 5 different brain networks: 1) the network of brain regions that subserves motor and sensory tasks (sensorimotor network); 2) the network of brain regions that subserves visual processing (secondary visual network); 3) the network of brain regions that subserves attention (ventral attention network); 4) the network of brain regions that subserves the processing of auditory and language information (language-processing network); and 5) the network of brain regions that subserves working memory (a form of short-term memory in which information is stored and manipulated) (left frontoparietal network) (46). In contrast, type 1 DM patients without microangiopathy have demonstrated increased connectivity in 2 of these brain networks compared with nondiabetic patients: the sensorimotor and secondary visual networks compared with nondiabetic patients: the network of brain regions that subserves motor and sensory tasks and the network of brain regions that subserves visual processing. Type 1 DM patients without microangiopathy have demonstrated decreased connectivity in the other 3 brain networks compared with nondiabetic patients: 1) the network of brain regions that subserves attention; 2) the network of brain regions that subserves the processing of auditory and language information; and 3) the network of brain regions that subserves working memory (46)
(Online Table 2). The increased connectivity in 2 of the networks of diabetic patients without microangiopathy (which we may consider an earlier stage in the course of diabetes compared with diabetic patients with microangiopathy) has also been observed early in the process of other pathological brain states such as multiple sclerosis and mild cognitive impairment (47,48). One explanation for this early-stage increased connectivity is that it is a compensatory reaction characterized by functional reorganization in attempts to maintain cognitive functions, occurring in response to early subtle brain damage. Indeed, as the severity of multiple sclerosis increases, brain network connectivity decreases (48).

III. ADIPOSITY. A total of 15 published imaging studies of the brain in association with measures of adiposity are included in this review (Online Table 3).

Structural brain changes. Global changes. Various indexes of increased adiposity such as increased body mass index (BMI), increased waist circumference, increased subcutaneous adipose tissue, and increased visceral adipose tissue have all been associated with total brain volume decreases (49–51).

Gray matter changes. Indexes of increased adiposity (most frequently BMI), have been consistently associated with regional brain GM volume decreases, although the location of these volume decreases has been inconsistent (52–55) (Online Table 3). Interestingly, some investigations report significant brain GM volume reductions in those considered obese (BMI >30) (51), whereas others report significant brain GM volume reductions in those considered simply overweight (BMI >25) (52,55). Indeed, the magnitude of cognitive impairment is associated with the magnitude of brain GM volume loss volume in those regions significantly affected by increased adiposity (53).

Finally, a higher BMI has been associated with decreased MRI neurochemical markers of neuronal integrity (N-acetylaspartate) in several brain GM regions (56,57) (Online Table 3).

WM changes. Reported brain WM volumetric changes associated with indexes of adiposity have been more inconsistent. Some have reported increased adiposity to be associated with brain WM volume increases (53), some have reported brain WM volume reductions (52), and yet others have reported no brain WM volumetric changes (51). We identified only 1 study for inclusion that evaluated the extent of MRI markers of brain microvascular disease in association with measures of adiposity that reported no association between several different indexes of adiposity and brain microvascular disease (50) (Online Table 3).

Brain WM neurochemical changes indicate greater adiposity to be associated with MRI indexes of decreased neuronal integrity in several brain WM regions (56). Moreover, MRI indexes of brain WM microstructural changes indicate that greater adiposity is associated with reduced brain WM connecting tract coherence in several regions, most consistently in the corpus callosum (largest WM structure in the brain, connecting the left and right cerebral hemispheres) (58–60), increased axonal damage in brain WM (59), and increased myelin damage in brain WM (61) (Online Table 3). Interestingly, greater aerobic fitness has been associated with greater coherence of brain WM in the same persons demonstrating a deleterious effect of increased adiposity on brain WM coherence (58).

Functional brain changes. Cerebral blood flow changes. Only a single study was identified for inclusion evaluating the effects of adiposity of brain blood flow that demonstrated a global decrease in brain blood flow in persons with increased adiposity (62).

Cerebral glucose metabolic changes. Negative correlations between adiposity and glucose metabolic rate in anterior regions of the brain have been identified (63), with a lower glucose metabolic rate in these regions associated with poorer cognitive performance (63).

IV. HYPERLIPIDEMIA. A total of 8 published imaging studies of the brain in association with hyperlipidemia are included in this review (Online Table 4).

Structural brain changes. GM changes. Higher total cholesterol and low-density lipoprotein (LDL) levels have been associated with lower total brain GM volume (64). Moreover, lower levels of high-density lipoprotein (HDL) cholesterol and higher levels of total cholesterol and non-HDL cholesterol have been associated with MRI indexes of reduced neuronal integrity in posterior brain regions (65).

WM changes. Structural MRI has not revealed any significant associations between lipid levels and WM volume (64) nor with MRI indexes of brain microvascular disease (66–68). MRI indexes of brain WM tract organization have been more revealing. For example, higher LDL, total cholesterol, and HDL have all been associated with widespread decreases in the coherence of brain WM tracts lateralized to the right hemisphere (69), with LDL levels showing the strongest associations and additional associations with imaging indexes of myelin integrity (69). Although higher triglyceride levels have been associated with decreased brain WM tract coherence, this association is weaker and less widespread compared with other lipid measures (69). Finally, treatment with lipid-lowering medication seems to have no effect on reversing the changes in brain WM associated with increased lipid measures (69).
Functional brain changes. Cerebral blood flow changes. Patients with hypertriglyceridemia have demonstrated decreased blood flow in select regions of the brain (65) (Online Table 4).

Cerebral glucose metabolic changes. Higher total cholesterol has been associated with decreased glucose metabolism in several brain regions (70) (Online Table 4). Use of lipid-lowering drugs had no effect on these findings (70). Moreover, a higher genetic risk of abnormal cholesterol has been associated with lower glucose metabolism in the same brain regions affected by high total cholesterol (71).

V. SMOKING. A total of 12 published imaging studies of the brain in association with smoking are included in this review (Online Table 5).

Structural brain changes. Global changes. Smokers have demonstrated significantly smaller total brain volume compared with nonsmokers (72). Moreover, greater lifetime exposure to tobacco has been associated with smaller total brain volume (72).

GM changes. Smokers have shown significantly smaller GM volume and lower GM density in multiple brain regions compared with never smokers (73,74) (Online Table 5). Among those who smoke, a greater lifetime exposure to tobacco has been associated with smaller total brain volume (72).

White matter changes. Structural MRI has revealed no significant effects of smoking on WM volume (76), nor MRI indexes of brain microvascular disease (77). However, smoking has been associated with increased coherence of brain WM tracts in the body of the corpus callosum (76).

Functional brain changes. Cerebral blood flow changes. Global brain blood flow during rest has not been shown to differ between smokers and nonsmokers (77). However, among smokers, acute administration of nicotine has been reported to induce a reduction in global brain blood flow during rest, more in the right than left hemisphere (78). Moreover, when considering individual brain regions, a bidirectional pattern of brain regional blood flow changes during rest has been seen in smokers acutely administered tobacco products, with some regions showing reductions and some increases (79) (Online Table 5).

Neurochemical and receptor changes. Monoamine oxidase B levels have been shown to be reduced in the brains of smokers compared with nonsmokers (80,81). In addition, nicotinic acetylcholine receptor density has been shown to be greater in several brain regions in smokers compared with nonsmokers (82) (Online Table 5). Smokers acutely exposed to cigarettes show greater post-smoking imaging indexes of increased dopamine release in several brain regions compared with smokers with no acute exposure (83).

VI. METABOLIC SYNDROME. A total of 7 published imaging studies of the brain in association with MetS are included in this review (Online Table 6).

Structural brain changes. GM changes. None of the selected studies for inclusion in this review assessed for brain GM changes in association with MetS.

WM changes. The prevalence of MetS has been reported to be higher in patients with silent brain infarcts (SBIs), an MRI-based indication of subclinical cerebrovascular disease (84,85). Moreover, among those persons with SBIs, those with a greater number of individual components of MetS demonstrated a greater burden of SBIs (84,85). The data on MRI indexes of brain microvascular disease are more mixed, with some showing no increase in MRI indexes of brain microvascular disease in persons with MetS (86,87), whereas others found increased MRI indexes of brain microvascular disease in persons with MetS (88). Limited data have demonstrated decreased organization and cellularity of the anterior portion of the largest WM connecting structure in the brain (corpus callosum) of patients with MetS (89). Among those with a diagnosis of MetS, MRI indexes of the organization of this WM connecting structure correlate with performance on various cognitive tasks (86) (Online Table 6).

Functional brain changes. Brain regional activation (fMRI) changes. MetS has been associated with reduced activation of several brain regions in patients performing cognitive tasks, detected by fMRI (90). Moreover, lower activation of these brain regions was associated with poorer performance on these cognitive tasks (90) (Online Table 6). Finally, these findings remained significant after controlling for the use of all medications used to treat components of MetS (90).

DISCUSSION

The results of this systematic review demonstrate that patients without symptomatic cardiovascular, cerebrovascular, or peripheral vascular disease but harboring risk factors for these diseases show significant structural and functional brain imaging changes (Table 1). Specifically, the risk factors of HTN, DM, increased adiposity, hyperlipidemia, and smoking are all independently associated with brain imaging changes. Moreover, the presence of an increasing number of individual VRF appears to increase the magnitude of these brain imaging changes as implied
by the MetS imaging data (Online Table 6). An important clinical manifestation of these VRF-related structural and functional brain imaging changes in these otherwise healthy persons is cognitive impairment.

The greater consistency of VRF-related functional brain imaging changes compared with structural changes in these asymptomatic at-risk persons, specifically, reductions in brain blood flow and glucose metabolism during rest, suggest early pathological changes in brain microcirculation affecting cerebral hemodynamics before the occurrence of detectable structural changes caused by atherosclerosis. Some potential changes include damage to mechanisms regulating vasomotor tone leading to enhanced vasoconstriction or reduced vasodilator responses (91), hypertrophy of the smooth muscles of precapillary resistance vessels, or perhaps reductions in the density of arterioles or capillaries in specific vascular beds (92,93).

Moreover, the redistribution of the normal pattern of hemodynamic and metabolic brain activation during a cognitive challenge observed in these asymptomatic patients harboring VRFs may indicate a compensatory mechanism invoked in response to early-stage dysfunction of the neuroarchitectural network that typically would support these cognitive tasks. These points are best illustrated in the observations of van Duinkerken et al. (46) wherein patients with DM with cerebral microangiopathy show decreased connectivity in 5 functional brain networks, whereas patients with DM without cerebral microangiopathy show decreased connectivity in 3 of these functional networks and increased connectivity in the remaining 2. This supports the notion of functional reorganization occurring in response to early subtle brain damage (effect of diabetes without microangiopathy), followed by a failing of this functional reorganization as disease severity increases (diabetes with microangiopathy). To investigate the possible structural substrates of the observed redistribution of the normal pattern of hemodynamic and metabolic brain activation during a cognitive challenge in asymptomatic persons harboring VRFs, correlations between metrics of WM tract connectivity demonstrated by MRI within and between coordinated brain regions would be revealing. Such techniques for visualizing brain complex white matter connections between neural networks formed by short connections among different cortical and subcortical brain regions currently exist and can be generated by tractography analysis of data collected by diffusion tensor imaging as depicted in Figure 1. Unfortunately, nearly all of the studies included in this review failed to acquire such data in conjunction with hemodynamic and metabolic brain data. Clearly, such investigations are warranted in the future.

Given that a greater number of patients in our aging population are projected to experience the development of mild forms of vascular cognitive impairment, this trend necessitates a better understanding of the mechanisms underlying their development and potential interventions to reverse or halt their progression. Indeed, cognition is the most important determinant of health status, quality of life, and functional ability in older age (94). Diminished cognitive capacity adversely affects a person’s ability to benefit from treatment for other medical problems (95). Given that the VRFs associated with the brain changes and cognitive impairments reviewed here are potentially modifiable, management of these modifiable factors could be a primary line of treatment. Indeed, the relationships between indexes of how effectively these VRFs are controlled (i.e., BP, HbA1c, BMI, total cholesterol, and LDL) and the severity of imaging abnormalities and related cognitive impairments reviewed here suggest that adequate treatment of these risk factors may have beneficial effects on brain function. Unfortunately, among the publications included in this review, analyses of medication effects on VRF-related brain imaging changes were scarce, but the limited evidence is compelling nonetheless. For example, antihypertensive treatment consistently blunted and/or reversed the decrease in global and regional brain blood flow and associated cognitive dysfunction in hypertensive patients. Therefore, future investigations of the treatment effects of VRFs on brain function and related cognitive abilities are sorely needed.

A precise summary of the somewhat disparate findings of brain imaging studies of VRFs was challenging due to a number of factors influencing outcomes. Although the selection of studies for inclusion in this review was based, in part, on the conduct of a minimal number of statistical corrections for confounds such as age, sex, and the presence of other VRFs, these variables did differ between studies. Other disparate factors that could have influenced the outcome of this review include age at onset of disease, duration of disease, and treatment status of the groups for these particular VRFs. Such confounds were inconsistently accounted for or data not provided at all. Moreover, studies differed in how the particular risk factor was defined (i.e., some studies used a dichotomous designation for HTN, whereas others used SBP and DBP as continuous variables in their analyses). Additionally, structural imaging methodology varied significantly between studies.
including the method to quantify the volume of the brain region of interest or the methodology of brain tissue type segmentation (i.e., GM, WM, cerebrospinal fluid), grading of WMH burden, or even the type of subclinical cerebrovascular pathology assessed. Moreover, comparing the findings of functional brain imaging studies that used various techniques for quantifying hemodynamic and metabolic changes was challenging.

Despite these limitations, this review represents an important endeavor given that the early identification and initiation of adequate treatment of these modifiable risk factors before the development of irreversible end-organ damage in the brain is an important clinical challenge that we must continue to address.

REPRINT REQUESTS AND CORRESPONDENCE: Dr. Joseph I. Friedman, Department of Psychiatry, Box 1230, The Mount Sinai Hospital, One Gustave L. Levy Place, New York, New York 10029. E-mail: jfriedman1@rcn.com.

REFERENCES


34. Last D, Allop DC, Abdullajal AM, et al. Global and regional effects of type 2 diabetes on brain
Brain Imaging Changes With CV Risk Factors


KEY WORDS
brain, cardiovascular, cerebral blood flow, cognitive, diabetes, glucose metabolic rate, gray matter, hyperlipidemia, hypertension, imaging, metabolic syndrome, obesity, smoking, vascular risk factor, white matter

APPENDIX For supplemental tables please see the online version of this article.

Go to http://cme.jaccjournals.org to take the CME quiz for this article.